Actavis Completes Forest Laboratories Acquisition LEARN MORE>
Actavis Completes Forest Laboratories Acquisition
>Go!

Executive Leadership

Driving continued growth, success and achievement

Executive Chairman Image

Executive Chairman

Paul M. Bisaro

Paul M. Bisaro currently serves as Executive Chairman of Allergan and the Company’s Board of Directors.

  • He served as the Chief Executive Officer of Actavis from September 2007 to July 2014. Prior to joining Actavis (then Watson), he was President and Chief Operating Officer of Barr Pharmaceuticals, Inc. (“Barr”) from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel and from 1997 to 1999 served in various additional capacities including Senior Vice President — Strategic Business Development at Barr. Prior to joining Barr, he was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds from 1989 to 1992. He also served as a Senior Consultant with Arthur Andersen & Co. Mr. Bisaro received his undergraduate degree in General Studies from the University of Michigan in 1983 and a Juris Doctor from Catholic University of America in Washington, D.C. in 1989.

CEO and President Image

CEO and President

Brenton L. Saunders

Brent Saunders is the Chief Executive Officer and President of Allergan.

  • Mr. Saunders was appointed Actavis’ CEO and President on July 1, 2014. Previously, he served as Chief Executive Officer and President of Forest Laboratories from 2013 to 2014 and served on the Company’s Board of Directors since August 2011. Prior to joining Forest, he served as the Chief Executive Officer and board member of Bausch + Lomb Incorporated from March 2010 until August 2013. Mr. Saunders served as a senior executive with Schering-Plough from 2003 to 2010, most recently as President of Global Consumer Health Care. He also served as Head of Integration for both Schering-Plough’s merger with Merck & Co. and for its $16 billion acquisition of Organon BioSciences. Before joining Schering-Plough, Mr. Saunders was a Partner and Head of the Compliance Business Advisory Group at PricewaterhouseCoopers LLP from 2000 to 2003. Prior to that, he was Chief Risk Officer at Coventry Health Care between 1998 and 1999 and a co-founder of the Health Care Compliance Association in 1995. Mr. Saunders began his career as Chief Compliance Officer for the Thomas Jefferson University Health System. He received a B.A. from the University of Pittsburgh, an M.B.A. from Temple University School of Business, and a J.D. from Temple University School of Law.

EVP & President, Generic and Global Operations Image

EVP & President, Generic and Global Operations

Robert Stewart

Bob Stewart was appointed President, Generics and Global Operations effective March 17, 2015.

  • Previously, Mr. Stewart served as Chief Operating Officer of Actavis since July 2014 and President, Global Operations and Executive Vice President, Global Operations, since August 2010. He joined Actavis (then Watson) in November 2009 as Senior Vice President, Global Operations. Prior to joining Watson, Mr. Stewart held various positions with Abbott Laboratories, Inc. from 2002 until 2009 where he most recently served as Vice President, Global Supply Chain. From 2005 until 2008, he served as Divisional Vice President, Quality Assurance and prior to this position served as Divisional Vice President for U.S./Puerto Rico and Latin America Plant Operations as well as Director of Operations for Abbott’s Whippany plant. Prior to joining Abbott Laboratories, Inc., he worked for Knoll Pharmaceutical Company from 1995 to 2001 and Hoffman La-Roche Inc. Mr. Stewart received B.S. degrees in Business Management/Finance in 1994 from Fairleigh Dickinson University.

EVP & President, International Brands Image

EVP & President, International Brands

Paul Navarre

Paul Navarre was appointed President, International Brands effective March 17, 2015.

  • Prior to assuming his current role, Mr. Navarre most recently served as Corporate Vice President & President, Europe, Africa and Middle East (EAME) of Allergan since July 2013. Previously, Mr. Navarre held various leadership positions at Allergan including Vice President, Neurosciences EAME and Vice President, Ophthalmology EAME. Mr. Navarre joined Allergan in 2007 as Senior Marketing Director for Ophthalmology, Europe and Country Manager, France. Before joining Allergan, Mr. Navarre spent 15 years at Procter & Gamble (P&G) in leadership roles of increasing responsibility within both their consumer and pharmaceutical divisions, serving in his last position as Country Manager for Australia, Austria, Switzerland, Finland, Sweden, Greece, and Portugal for the P&G Pharmaceutical business. Mr Navarre holds a Master’s degree in Business Administration from the Institut Supérieur du Commerce (ISC Paris Business School).

EVP & President, Branded Pharma Image

EVP & President, Branded Pharma

William Meury

Bill Meury was appointed President, Branded Pharma effective March 17, 2015.

  • Mr. Meury joined Actavis in July 2014 as Executive Vice President, Commercial, North American Brands. Prior to joining Actavis, he served as Executive Vice President, Sales and Marketing, Forest Laboratories, Inc. He joined Forest in 1993 and held positions in Marketing, New Products, Business Development, and Sales. Most recently, as Executive Vice President, Sales and Marketing, Mr. Meury oversaw the activities of several departments including Product Management, Market Research, and Commercial Assessments, as well as Forest’s Global Marketing and Early Commercialization groups. Mr. Meury directed 10 product launches during his tenure at Forest. Before joining Forest, Mr. Meury worked in public accounting for Reznick Fedder & Silverman and in financial reporting for MCI Communications. He has a B.S. in Economics from the University of Maryland.

EVP & President, Allergan Medical Image

EVP & President, Allergan Medical

Philippe Schaison

Philippe Schaison was appointed President, Allergan Medical effective March 17, 2015.

  • Previously, Mr. Schaison served as Corporate Vice President and President of U.S. Medical of Allergan since September 2013. Before joining Allergan, Mr. Schaison held various leadership positions at Clarins including Global President Worldwide Travel Retail; President, Latin America and Middle East, Africa; and as a member of the Executive Committee. Previously, he served as the CEO of Aesthetic Factors, an aesthetic startup; Vice President of Global Skin Care for Johnson & Johnson; in various General Manager positions at L’Oreal leading Southern Europe, the Middle East, and India, Vichy L’Oreal USA, and Greece; as the lead for Arthur D. Little Consulting Philadelphia (U.S.) Health Care Practice; and in a number of sales and marketing positions at Merck & Company. Philippe is also a Board Member of the Galien Foundation, which oversees and directs activities in the United States for the Prix Galien, an international award regarded as the equivalent of the Nobel Prize in biopharmaceutical research. He holds an MBA from Hautes Etudes Commerciales (H.E.C.) and a PharmD. from University of Paris V.

EVP, Brand R&D Image

EVP, Brand R&D

C. David Nicholson, PhD

David Nicholson was appointed head of Brand R&D effective March 17, 2015.

  • Dr. Nicholson joined Actavis as Senior Vice President, Global Brands R&D in August 2014. Previously, he served as Chief Technology Officer and EVP, R&D for Bayer CropScience from March 2012 to August 2014; Vice President of Licensing and Knowledge Management at Merck from 2009 to December 2011; and Senior Vice President, responsible for Global Project Management and Drug Safety at Schering-Plough from 2007 to 2009. From 1988 to 2007, Dr. Nicholson held various leadership positions at Organon, where he most recently served as Executive Vice President, Research & Development and was a member of the company’s Executive Management Committee. He received a B.Sc. from the University of Manchester and his Ph.D. from the University of Wales.

EVP, Chief Financial Officer Image

EVP, Chief Financial Officer

Maria Teresa Hilado

Maria Teresa (Tessa) Hilado is Allergan Chief Financial Officer.

  • Ms. Hilado was appointed Actavis’ CFO on December 8, 2014. Prior to joining Actavis, Ms. Hilado served as Senior Vice President, Finance and Treasurer for PepsiCo, Inc. since 2009. Before joining PepsiCo, she previously served as Vice President and Treasurer for Schering-Plough Corporation from 2008 to 2009. Before joining Schering-Plough, Ms. Hilado spent more than 17 years with General Motors Corporation in leadership roles of increasing responsibility, most notably Assistant Treasurer from 2006 to 2008 and CFO, GMAC Commercial Finance LLC from 2001 to 2005. She began her career with Far East Bank and Trust Company, Manila, Philippines. Ms. Hilado received a B.S. in Management Engineering from Ateneo de Manila Univeristy in the Philippines, and an MBA from the University of Virginia’s Darden School of Business Administration.

EVP, Chief Legal Officer and Corporate Secretary Image

EVP, Chief Legal Officer and Corporate Secretary

A. Robert D. Bailey

Bob Bailey was appointed Chief Legal Officer and Corporate Secretary effective July 1, 2014.

  • Previously, Mr. Bailey served as Senior Vice President, Chief Legal Officer, General Counsel and Corporate Secretary of Forest Laboratories, Inc. He previously served from 2007 to 2013 as Executive Vice President, Law, Policy and Communications at Bausch + Lomb. Before joining Bausch + Lomb in 1994, Mr. Bailey was an attorney at Nixon Peabody (formerly Nixon Hargrave Devans & Doyle). Mr. Bailey received his law degree from the University of Minnesota and his undergraduate degree from St. Olaf College in Northfield, MN.

EVP, Chief Human Resources Officer Image

EVP, Chief Human Resources Officer

Karen Ling

Karen Ling was appointed Chief Human Resources Officer effective July 1, 2014.

  • Prior to joining Actavis, Ms. Ling served as Senior Vice President and Chief Human Resources Officer for Forest Laboratories, Inc. Ms. Ling joined Forest in January 2014 from Merck & Co., Inc., where she served as Senior Vice President, Human Resources, for the company’s Global Human Health and Consumer Care businesses worldwide. Prior to that role at Merck, she was Vice President, Compensation and Benefits. Before Merck, Ms. Ling was Group Vice President, Global Compensation & Benefits at Schering-Plough. She also spent 14 years at Wyeth in various positions of responsibility in human resources as well as in Wyeth Pharmaceutical’s Labor and Employment Department. Prior to joining Wyeth, Ms. Ling practiced corporate law with Goldstein and Manello, P.C. in Boston. Ms. Ling holds a B.A. from Yale University and a J.D. from Boston University School of Law.

EVP, Global Chief Compliance Officer Image

EVP, Global Chief Compliance Officer

Jonathon Kellerman

Jonathon Kellerman was appointed Global Chief Compliance Officer in December 2014.

  • Prior to joining Actavis, Mr. Kellerman spent 20 years with PricewaterhouseCoopers LLP (PwC) in leadership roles of increasing responsibility, most recently 10 years as Partner in the company’s Pharmaceutical & Life Sciences Advisory practice. Mr. Kellerman was responsible for helping lead the firm’s Governance, Risk & Compliance practice. He has extensive experience in compliance strategy and commercial performance improvement, including global anti-bribery/anti-corruption program assessment, design and implementation work; building and implementing effective global compliance programs; managing fraud investigations and remediation activities; re-engineering processes supporting key commercial and R&D business activities and compliance controls; and re-designing how companies engage health care professionals. Mr. Kellerman received a B.A. in Sociology from Franklin & Marshall College.

EVP, Corporate Business Development Image

EVP, Corporate Business Development

Sigurd Kirk

Sig Kirk was appointed head of Corporate Business Development effective March 17, 2015.

  • Previously, Mr. Kirk served as Actavis’ Senior Vice President, Corporate Business Development since May 2012. He joined Actavis (then Watson) in 2009 as Vice President, Integration. Before joining Watson, Mr. Kirk served as Senior Vice President, Global Controller and Chief Accounting Officer for Barr Pharmaceuticals, Inc., which was subsequently acquired by Teva Pharmaceuticals. He also served as an Audit Manager at Deloitte and Touche LLP. Mr. Kirk has more than 20 years of finance and operations experience in both public and private companies in the pharmaceutical, consumer product, media and technology industries. He received a B.A. from Pace University.

EVP, Chief Strategy Officer Image

EVP, Chief Strategy Officer

Sanjiv Patel

Sanjiv Patel was appointed Chief Strategy Officer effective March 17, 2015.

  • Prior to assuming his current role, Mr. Patel led Allergan’s Global Strategic Marketing and Health Outcomes function as well as leading the company’s global initiative to increase effectiveness and efficiency. Previously, Mr. Patel held various leadership positions at Allergan including leading the company’s Emerging Markets commercial operations across all product lines in over 40 countries. He also led the acquisition and integration of new affiliates in Russia and South Africa and the expansion of Allergan's indirect footprint in the Middle East and Africa. Prior to that, Mr. Patel led commercial teams in Allergan’s European Aesthetics Franchise. Before joining Allergan, Mr. Patel practiced as a surgeon before joining the Boston Consulting Group where he focused on strategy and the execution of large scale transformations with clients across the healthcare value chain. He has a Neurosciences degree from Cambridge University, a Medical degree from the University of London, an MBA from INSEAD and is a member of The Royal College of Surgeons of England.

EVP, Chief Communications Officer Image

EVP, Chief Communications Officer

Alex Kelly

Alex Kelly was appointed Chief Communications Officer on April 20, 2015.

  • Previously, Mr. Kelly served as Senior Vice President, Chief Integration Officer since July 1, 2014. In this role, he led the integration of Forest Laboratories following its acquisition by Actavis. He also co-led the integration of Allergan. Prior to joining Actavis, Mr. Kelly was Senior Vice President, Chief Communications Officer, Public Affairs and Investor Relations at Forest Laboratories. In that role, he led Forest’s corporate communications and investor relations programs, including internal and external communications, media relations, corporate branding, product communications, and public affairs. While at Forest, Mr. Kelly led the integration of Aptalis Pharma following its acquisition in January 2014. Prior to Forest, Mr. Kelly served as Vice President, Investor Relations at Bausch + Lomb. Mr. Kelly was Senior Vice President, Investor Relations at Merck & Co., Inc. following the combination with Schering-Plough where he led the Global Communications and Investor Relations team. He previously worked for Novartis as Executive Director, Investor Relations, after spending 14 years at Pharmacia, including ten years in pharmaceutical sales and sales management and four years in investor relations. Mr. Kelly holds a Bachelor of Science in Pharmacy from Purdue University, where he graduated Cum Laude.